ODT’s Most-Read Stories This Week—June 18

Clinical trial news, M&A, and an FDA clearance garnered the most page views on ODT’s website this past week. 

Driving the most traffic, however, was Zimmer Biomet’s $1.25 million support for the American Association of Hip and Knee Surgeons’ (AAHKS) new Fellowship Education Improvement and Innovation (FEII) Grant Program. The grant will fund Adult Reconstruction Fellowship Programs, which will be incentivized to address targeted areas of improvement, including patient optimization, high-risk/at-risk patients, diverse patient populations, site of care impact, registry-based research and advanced technologies in joint arthroplasty. The grant program is intended to be flexible and Inclusive, with long-term goals to standardize curriculum, improve training and financially support adult reconstruction fellowship training nationally.

Also garnering interest was Red Point Medical 3D’s (RPM-3D) milestone, having become the first patient-specific instrumentation-based company cleared by the FDA to market patient-specific bone cutting guides for use in foot and ankle reconstructive surgeries such as bunion correction. RPM-3D’s patent pending, patient-specific surgical guide system utilizes proprietary AI software (RedPoint Intelligence) to convert data derived from a CT scan of the patient’s foot and/or ankle into a 3D model, which is then manipulated to resemble the desired correction as prescribed by the surgeon. 

OrthoPediatrics earned page views for its $33 million purchase of Pega Medical, and both Ortho RTI and MIMEDX generated traffic for their respective clinical trial news. Ortho RTI began enrolling patients in its U.S. Phase I/II rotator cuff repair study; recruitment is taking place at selected sites in Arizona, Florida, Indiana, Pennsylvania, and Virginia. MIMEDX, meanwhile, is working with Nordic Bioscience Clinical Development A/S (NBCD) to run registrational trials for its placental biological knee osteoarthritis treatment. Image Analysis Group will also provide advanced tools to detect the potential for MIMEDX’s placental biologic injectable—micronized dehydrated Human Amnion Chorion Membrane (mdHACM)—to act as a Disease Modifying Osteoarthritis Drug (DMOAD) and potentially moderate the disease’s progression. MIMEDX plans to begin its knee osteoarthritis (KOA) clinical trial later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints. 

1. Zimmer Biomet Funds $1.25M Grant Aimed at Optimizing Orthopedic Care

2. Red Point Medical 3D’s Bunion Surgery System Cleared by FDA

3. OrthoPediatrics Corp. to Acquire Pega Medical

4. Ortho RTI Begins Rotator Cuff Repair Trial

5. MIMEDX Enlists Nordic Bioscience for Knee Osteoarthritis Therapy Trial Help